Donanemab: What is the new Alzheimer’s drug rejected by the NHS?
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research
Alzheimer’s drug rejected for widespread use by NHS spending watchdog
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”.The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.
Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report
U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive. Read more here.
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
A second Alzheimer’s drug has been rejected as too expensive by the UK’s healthcare spending watchdog despite being approved as safe and effective by the country’s medicines regulator. The decision by the National Institute for Health and Care Excellence to reject Eli Lilly’s donanemab came two months after it similarly ruled that lecanemab,
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
New Alzheimer’s drug approved in UK, but government won’t pay for it
The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months. View on euronews
Alzheimer's Society responds to approval of new Alzheimer's drug
The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday, October 23, that it has approved the drug donanemab.
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns - Campaigners say decision is ‘frustrating setback’ for people living with disease
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...
Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Medpage Today on MSN9d
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of Millions
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
Lifetime Achievement Award, Lecanemab And Biomarkers In Focus At CTAD
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Finanznachrichten5h
Biogen Inc.: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...